Posted in:News Eli Lilly Files PGR Petition against Genentech’s IL-17A/F Heterodimer Patent By Caitlin M. Wilmot April 17, 2019 Comments are off On April 2, 2019, Eli Lilly and Company (“Lilly”) filed a Petition for Post-Grant Review (“PGR”) of Genentech’s U.S. Patent... Read more Tagged with: Eli Lilly, Genentech, News, PGR, PTAB http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Genentech Files Suit Alleging Eli Lilly’s Taltz® Product Infringes a Newly Issued Genentech Patent By Seth Cockrum July 16, 2018 Comments are off On July 2, 2018, Genentech filed suit against Eli Lilly and Company (“Lilly”) in the Southern District of California alleging Lilly’s... Read more Tagged with: Eli Lilly, Genentech, ixekizumab, News, Taltz® http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Lilly Announces Positive Results for Galcanezumab in Treating Episodic Cluster Headaches By Seth Cockrum May 25, 2018 Comments are off Last week, Eli Lilly and Company (“Lilly”) announced that galcanezumab met its primary endpoint in a Phase 3 study of patients with... Read more Tagged with: Aimovig™, Alder Biopharmaceuticals, Amgen, Eli Lilly, eptinezumab, erenumab, FDA, fremanezumab, galcanezumab, News, Novartis, Teva http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Novartis and Amgen Announce FDA Approval of Aimovig™ By Seth Cockrum May 23, 2018 Comments are off Last week, Novartis and Amgen announced the FDA approved Aimovig™ (erenumab) for the preventive treatment of migraine in adults. The... Read more Tagged with: Aimovig™, Alder Biopharmaceuticals, Amgen, Eli Lilly, erenumab, FDA, Novartis, Teva http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Global Approvals for Insulin Glargine Promise a More Affordable, Long-Acting Treatment for Diabetes By Caitlin M. Wilmot April 3, 2018 Comments are off Last week, Mylan N.V. and Biocon Ltd. announced that their jointly-developed insulin glargine biosimilar, Semglee™, received marketing... Read more Tagged with: Abasaglar™, Biocon, Eli Lilly, FDA, Insulin glargine, Lantus®, Lusduna™, Merck, Mylan, Sanofi, Semglee™, trastuzumab http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus